Chengdu HUITAI Biomedicine is a clinical-stage biotech company focused on developing pan anti-fibrotic peptides through novel TGF-β technology. Unlike conventional TGF-β inhibitors that target integrins or TGF-β directly, HUITAI's lead asset, HTPEP-001, selectively antagonizes the interaction between TSP-1 and CD36 to block TGF-β1 activation.
Currently, we are developing a groundbreaking new drug aimed at treating Idiopathic Pulmonary Fibrosis (IPF) by targeting the activation of TGF-β1. Notably, there are no comparable competitors globally. This drug has successfully completed Phase I clinical trials in Beijing, China. We are now preparing to submit a first-in-class new drug clinical trial application to the FDA.
